A 53-year-old wom an was refe rred to our clinic for evaluation of a left anterior neck mass that was consisten t with a thyroid goiter. She denied any systemic symptoms, and she was clinica lly euth yroid. Her only complaint was mild dysphagia of severa l months' duration, but she denied any significant weight loss.
On physical exam ination, the mass was firm and measured 4 x 5 ern. Compu ted tomography (CT) confirmed its location in the left thyroid lobe (figure 1). The mass appeared to be confin ed to the thyroid, and no pathol ogic cervic al adenopathy was evident. Findings on fine-needl e aspiration biopsy were indeterm inate.
The patient was taken to the opera ting roo m, where she underwent a total thyroidectomy (figure 2).Fin al pathology identified the mass as a columnar cell variant of papillary thyroid carcinoma (PTe).The tumor was encapsulated and showed no evidence of extrathyroidal spread. The columnar cell variant of PTC was first reported by Evans in 1986.
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Asimilaradverse event profilewasobserved inthe subgroup ofpediatric patients6to12yearsofage. Twotothree percent (2-3%) of patients in clinical trials discontinued because of adverse events. Systemic corticosteroid side effects were not reported during controlled clinical studies with RHI NOCORT AO UA Nasal Spray. If recommended doses areexceed ed, however, or if individuals are particularly sensitive, symptoms ofhypercorticism. ie, Cushing's Syndrom e, coul doccur. Rare adverseevents reportedtrom post-marketing experience include: nasal septum perforati on, phar ynxdisorders (throat irritation, throat pain, swollen throat. burning throat, and itchy throat), angioedema. anosmi a, and palpitations. Cases ofgrowthsuppressionhave been reported forintranasal corticosteroids incl uding RHINOCORT AOUA NasalSpray (see PRECAUTIONS, Pediatric Use). cell variants did contain areas ofpapillary architecture, they were distinguished by the elonga ted (hence, "col umnar") cells, whose nuclei were stratified and appeare d to be rich in chromatin ( figure 3, A) . The class ic nuclear features of PTC-includ ing optical clearing, grooves, and inclu sions ( figure 3, B) -were rarely seen. The appearance of the columnar cells was similar to that of another subtype of PTC , the tall-cell variant, which was first reported by Hawk and Hazard in 1976 . 6 Even so, histology revealed that the tall cells had more features in co mmon with typical PTC . than with the columnar cell variant.
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The co lumnar cell varia nt has since been recognized by the World Health Organization as a distinct entity under the subheading of "aggress ive variants" of PTe. However, this classification is controvers ial becau se this disease has a tenden cy to metastasize hematogenously to the lungs and bones; therefore, many believe the co lumnar cell variant should be categori zed as a subtype offollicular thyroid car cinoma. Oth ers belie ve that the disease merit s its own category as a speci fic type of thyroid carcinoma located along the spectrum of disease toward the poorl y differenti ated form s.
The columnar cell variant of PTC can pose a diagnostic challenge ." For exa mple, it may be interpreted on initial fine-needl e aspiration studies as typic al PTe. Also, the microscopi c appeara nce of a columnar cell specimen may lead a path ologist to co nsider metastatic adenoca rcinoma. Immunohistochemical staining can be an impo rtant diagnostic aid in these cases; columnar cell variants of PTC should be negative for carc inoembryonic antigen and positive for thyroglobulin unless the cells are too poorly different iated.
Contro versy also surrounds the actual clinical course and prognosis of this disease. Both Eva ns? and Wenig et aP reported favora ble prognoses in some patients-particuVolume 85, Number 10 larly with respect to the few cases that involved women . In most of these successfully treated cases, the tumors were encapsulated and had not undergone extrathyro idal invasion, and these patients survive d without evidence of recurrent disease. In view of these findings, it has been sugges ted that the column ar cell variant should not necessarily be treated as an aggress ive subtype of PTC; instead, treatm ent should be based on clinical stagi ng, with a focus on tumor encapsulation and invasi on bey ond the confines of the thyroid gland. It is also possible that this particular tumor may have a greater tendency toward encapsulation in female patient s, thus providing added protection fro m extrathyroidal invasio n.
